TAS-116

DRUG3 trials

Conditions

Advanced Breast CancerAdvanced Solid TumorsAdvanced or Metastatic Solid TumorAlveolar Soft Part SarcomaBiliary Tract CancerBladder CancerColorectal CancerEndometrial Cancer

Phase 1

A Study of TAS-116 in Patients With Solid Tumors

CompletedNCT02965885

Taiho Oncology, Inc.Advanced Solid Tumors

Start: 2017-07-10End: 2019-05-03Updated: 2024-09-04

AB122 Platform Study

RecruitingNCT04999761

Taiho Pharmaceutical Co., Ltd.Advanced or Metastatic Solid Tumor, Alveolar Soft Part Sarcoma, Biliary Tract Cancer +6

Start: 2021-06-01End: 2026-05-31Target: 917Updated: 2024-09-25

TAS-116 Plus Palbociclib in Breast and Rb-null Cancer

WithdrawnNCT05655598

Brown UniversityAdvanced Breast Cancer, Bladder Cancer, Endometrial Cancer +4

Start: 2023-09-12End: 2024-08-05Updated: 2024-09-19

Related Papers

Pooled safety analysis of pimitespib for the treatment of patients with advanced gastrointestinal stromal tumors.

2025-11-20

Zimberelimab platform study: Safety and efficacy of zimberelimab in combination with futibatinib and chemotherapy in patients with first-line advanced or metastatic esophageal carcinoma.

Journal of Clinical Oncology2025-01-27

BrUOG 387: Phase Ib investigator-initiated trial of a heat shock protein 90 inhibitor (HSP90i) combined with a CDK4/6i in advanced breast cancer progressing on CDK4/6i and in solid tumors with retinoblastoma (Rb)-deficiency (IND163592).

Journal of Clinical Oncology2023-06-011 citations

First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in advanced solid tumors.

Journal of Clinical Oncology2017-05-204 citations

TAS-116

Sponsors

Conditions

Phase 1

Related Papers